Boan says nivolumab biosimilar BA1104 met its China Phase 3 endpoint

Shandong Boan Biotechnology (HKEX: 06955) said on Nov 17, 2026 that BA1104 (LY01015, nivolumab) met the primary endpoint of China Phase 3 trial NCT06022861. The registry still lists the study as active, not recruiting.

Shandong Boan Biotechnology (HKEX: 06955) said on November 17, 2026 that the China phase 3 trial of BA1104 (LY01015), its nivolumab injection, has been completed and met its primary endpoint, and that the company will shortly file a marketing application with the National Medical Products Administration. Boan calls BA1104 the first Opdivo biosimilar to finish a phase 3 trial in China, and says it intends to seek the indications for which Opdivo is approved in China, citing China’s technical guidelines on biosimilar similarity evaluation and indication extrapolation. The filing gives neither the response rates, the equivalence margins, nor the number of patients in the analysis.

The registered study is NCT06022861. Checked on November 17, ClinicalTrials.gov still lists it as active, not recruiting, with an estimated enrollment of 510, a primary-completion date of May 17, 2026 and a study-completion date of October 30, 2026. No results are posted. The record’s primary endpoint is independent-review objective response rate from baseline to week 16. Participants are adults with previously untreated unresectable advanced, recurrent or metastatic esophageal squamous-cell carcinoma and a PD-L1 tumor proportion score of at least 1%. Both arms use fluorouracil plus cisplatin. LY01015 or Opdivo is given at 240 mg every two weeks during chemotherapy, then 480 mg every four weeks in maintenance. On the Opdivo arm, that maintenance is specified as within 24 weeks, after which the control treatment converts to LY01015 480 mg every four weeks.

Boan’s announcement describes a randomized, double-blind comparison of BA1104 and Opdivo, each plus chemotherapy, in advanced or metastatic esophageal squamous-cell carcinoma. It says the confidence interval for the objective-response-rate ratio fell entirely inside the prespecified equivalence margins, and that independent central review agreed with investigator assessment. It also says disease control, progression-free survival and overall survival were highly similar, with no clinically meaningful efficacy difference, and that anti-drug and neutralizing antibody rates were low and comparable. It does not state the week-16 window, the PD-L1 threshold, or the control-arm switch. Because the registered Opdivo arm converts to LY01015, later progression-free and overall survival in this protocol are not a continuous originator-versus-biosimilar comparison. The week-16 response endpoint sits earlier in the schedule than that conversion.

The same filing says a prior Biosimilar Biological Product Development Type 2b meeting with the U.S. Food and Drug Administration ended with agreement that a U.S. biologics application could rest on one pharmacokinetic similarity study, without a phase 3 trial. That account is the company’s. Separately, Boan says a single-dose phase 1 study in healthy Chinese men found the 90% confidence intervals for the geometric-mean ratios of AUC0–∞, AUC0–t and Cmax all inside 80.00%–125.00%, and that those results were published in BioDrugs.

The China file Boan described is an efficacy-equivalence package plus an extrapolation request. The U.S. path it described is a pharmacokinetic file. Neither the acceptance number in China nor a U.S. application date is in the November 17 announcement.

The next records are the NMPA acceptance number, a ClinicalTrials.gov results or status change for NCT06022861 that shows the week-16 response rates and margins, and any U.S. filing that tests the pharmacokinetic-only plan.

Checked November 17, 2026 against Boan’s English voluntary announcement and the ClinicalTrials.gov record NCT06022861.